Press Release
24 November 2017
Nasdaq Stockholm's Listing Committee Has Approved Immunicum's Shares for Listing on Nasdaq Stockholm Conditional Upon Completion of the Rights Issue
Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing an off-the-shelf immune system primer against a range of solid tumors, today announced Nasdaq Stockholm's listing committee has conditionally approved Immunicum's shares for listing on Nasdaq Stockholm. The approval is conditional upon Immunicum fulfilling the formal listing requirement of having secured sufficient working capital for a period of twelve months following the first day of trading on Nasdaq Stockholm. Immunicum has previously communicated a 90 percent secured Rights Issue of up to SEK 223 million. The secured amount of SEK 200 million ensures that Immunicum is financed until the end of 2019 based on planned activities.
The approval from the listing committee is also subject to completion of customary conditions, including the Swedish Financial Supervisory Authority's approval and registration of a prospectus.
The subscription period for the Rights Issue is expected to be on or about 8-22 December 2017. Subject to the fulfilment of the above conditions, including completion of the Rights Issue, the first day of trading on the Nasdaq Stockholm exchange is preliminarily planned to be during January 2018. The Company will communicate the timetable for the listing on Nasdaq Stockholm as soon as it has been established.
"We welcome this decision from the Listing Committee and appreciate their guidance. I would like to recognize the Immunicum team who has worked diligently to maintain the requirements over the last months to support the move to the main market," said Carlos de Sousa, CEO of Immunicum. "We look forward to the completion of the Rights Issue and thank our shareholders in advance for their support."
Advokatfirman Delphi acts as legal advisor to Immunicum in connection with the listing on Nasdaq Stockholm.
The information is information that Immunicum is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above on 24 November 2017, at 4:30 p.m. CET.
For more information, please contact:
Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com
Investor Relations Sweden
Helena Stångberg Hallvarsson & Halvarsson Telephone: + 46 709 71 12 53 E-mail: ir@immunicum.com
Investor and Media Relations EU/US
Gretchen Schweitzer Trophic Communications Telephone: +49 172 861 8540 E-mail: ir@immunicum.com
The Company's Certified Adviser is Redeye AB Telephone: +46 (0)8 545 013 30 www.redeye.se
| About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq First North Premier. www.immunicum.com |
